Solvias to Present Groundbreaking Insights on Gene Therapy Safety at ASGCT 2025#United_States#New_Orleans#gene_therapy#Lentiviral_Vector#Solvias
Solvias to Present Groundbreaking Insights on Gene Therapy Safety at ASGCT 2025
At ASGCT 2025, Solvias will unveil innovative approaches to enhancing safety in gene therapy development, particularly focusing on lentiviral vectors.
third-news.com
May 6, 2025 at 2:55 PM
Solvias to Present Groundbreaking Insights on Gene Therapy Safety at ASGCT 2025#United_States#New_Orleans#gene_therapy#Lentiviral_Vector#Solvias
VIVEbiotech Partners with Ampersand Capital for Growth in Lentiviral Vector Manufacturing#Spain#Ampersand_Capital#VIVEbiotech#Lentiviral_Vector#San_Sebastián
VIVEbiotech Partners with Ampersand Capital for Growth in Lentiviral Vector Manufacturing
VIVEbiotech announces a significant investment from Ampersand Capital Partners aimed at boosting lentiviral vector production capacity to meet rising demands in gene therapy.
third-news.com
December 4, 2024 at 10:03 AM
VIVEbiotech Partners with Ampersand Capital for Growth in Lentiviral Vector Manufacturing#Spain#Ampersand_Capital#VIVEbiotech#Lentiviral_Vector#San_Sebastián